MedTrace Logo

Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.

NCT05135052 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-05-14

No results posted yet for this study

Summary

Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study.

Conditions

  • Non-melanoma Skin Cancer

Interventions

DEVICE

Rhenium-SCT

Rhenium-SCT irradiation device

Sponsors & Collaborators

  • OncoBeta Therapeutics

    lead INDUSTRY

Principal Investigators

  • Gerhard Dr Dahlhoff, MD · Oncobeta GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2026-07-15
Completion
2027-05-15

Countries

  • Australia
  • Austria
  • Germany
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135052 on ClinicalTrials.gov